))
Ep 14 | All About 340B Grantees (Part 2)
Manage episode 357160988 series 3374171
A tartalmat a SpendMend Pharmacy biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a SpendMend Pharmacy vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
This is part two of our two-part series focusing on 340B grantee-covered entities. The team talks about the importance of maintaining auditable records (15:34) and the challenges that many grantees face in meeting this 340B eligibility requirement. Also, they cover important billing considerations related to Medicaid Duplicate Discount prevention (31:20). Finally, the group debates future developments that 340B grantee-covered entities should keep on their radar through 2023 (45:52).
But first, Greg and Rob catch up on 340B implications from the Consolidated Appropriations Act of 2023 and share insights from a recent publication (J Manag Care Spec Pharm. 2023;29(3):229-35) that predicts which drugs will be subject to Medicare price negotiations starting in 2026 and beyond.
58 epizódok
Megosztás
